CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion - Wikidata - wikimedia - TriplyDB

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

http://www.wikidata.org/entity/Q24634660

about

Antidepressants for smoking cessation New mechanisms and perspectives in nicotine withdrawal Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans Pharmacogenetic Optimization of Smoking Cessation Treatment.Organic cation transporter variation and response to smoking cessation therapies Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial.Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies.Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects.

P2860

Q24201167-7219F56F-FB1E-48E2-950F-7496D0B5CF56 Q28111991-7753204F-0BFB-477F-A846-D929D97C5EBD Q28247305-A181C8CB-ED6B-469F-A90C-30BA3C437DF5 Q33953232-3EDE2853-D0A6-4333-B32F-19AB40F807C8 Q34540994-361E5659-A5E3-4E5F-B85F-E51D08B3DC6C Q34542169-F2049E41-CEE7-4B26-A114-C9288D471C5F Q34974830-B7D2F7A3-2D07-467F-B766-C92C9C765CF0 Q35694111-1493F891-7136-4C80-9CF9-5207E39B9692 Q35751986-52F2C162-006B-45F6-823D-285B0C3DAF55 Q36737009-C0478970-EF61-4711-83D4-98877609752C Q36900154-5163AC7A-A9D0-43B7-8696-5C191DEA5696 Q37148882-2169D47F-1263-4461-BC9B-0939E6EE4092 Q37273823-2BA69B00-12D0-4203-BB12-72F10DD8DBB8 Q37325773-F5F4BFC8-D41D-4AD0-9EBE-06C3C2F4561D Q37596743-1294E1A1-4CD8-49E4-B0E9-C64C28EF225E Q39519725-E83C8289-D9A4-4F0E-B2E0-006C3C833DF5 Q42407006-822CEA36-3876-4B26-9197-C01A578AE900 Q42713259-AA3BCC19-D99B-43F7-B5FB-F9893640B0E5 Q46472801-9CDF3F6C-990B-48CD-838B-12418CCCF7CC Q47267937-931AA486-C0B8-468A-BF18-C000B15E9C2D Q48015634-93D5F8EC-BAA7-4186-9236-9C0DB245F18B Q48285456-9D73E57C-0C5E-4594-922D-3C6E1873D910 Q54260617-3B744CC4-637A-46A3-9BFF-BB0DA9A9AFD3 Q54412899-4D83353A-F5C7-4090-B636-FC3D3E19C429 Q55262171-17C3F385-37F0-4033-B673-26EC77C80AC0

P2860

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

http://www.wikidata.org/entity/Q24634660

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@ast

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@en

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@nl

type

label

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@ast

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@en

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@nl

prefLabel

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@ast

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@en

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@nl

P1433

Q24634660-5688A2DC-28E6-47D1-94C2-7319B1518AD7

P1476

Q24634660-0DA2F20E-1D4E-4CFE-9E52-FB58F2369586

P2093

Q24634660-0BF5072B-8848-45F4-A1E9-FD2A8D2CDB50

Q24634660-101AC281-7675-4594-8654-516B62E933BB

Q24634660-3EB8FD2D-A42F-41F9-A75D-5D0EDA44A1AC

Q24634660-5386A6F2-A500-4E9E-A6A2-0D7D123F644C

Q24634660-7888BD07-530D-492D-AE61-198CA13616B3

Q24634660-B4B4147B-BF96-43A0-8BCC-9793EDB1B157

Q24634660-D6EEEC2C-BACC-4C9C-8DDE-AA4E96CD7183

Q24634660-D8592BF7-E65C-474E-B863-1FBA6D42EC8D

P2860

Q24634660-03820050-CA31-4DF5-9A8A-D657D492819A

Q24634660-0458691C-DFB1-4FFD-949B-E6F1B8404C97

Q24634660-05A15FB7-61BA-4124-9D6C-8FBAA0A0C2F9

Q24634660-0DC2F698-7D67-40E3-8409-637A200D2093

Q24634660-0DDAF77D-68DF-40A1-8FEB-2002A1542906

Q24634660-1AF70C0B-1D7E-4C2A-B471-62BCD6590343

Q24634660-2F8171AC-D5AF-4F91-8927-A96E5D9D7759

Q24634660-2F95CBF7-80B0-4FD9-8B5E-7E93FAF78DEB

Q24634660-3153BB80-B502-4593-9E0C-FAB692E584FF

Q24634660-37DD821E-CF26-4E5B-8B72-CC3C80DD160D

P304

Q24634660-5AFB05A5-56CE-47DB-8746-1E4C5B5F344B

P31

Q24634660-ECB5F6E5-8E55-471D-8265-B720A3697F34

P356

Q24634660-B980148D-A8A0-4AAD-A953-9D176573BF5E

P407

Q24634660-D7DD42EF-4CC1-4827-9ECF-AB3C699D3CFF

P433

Q24634660-5DA9BD67-4945-4D6D-AD0D-99E2DE10F7A9

P478

Q24634660-E491A3FE-911B-4D9A-A95C-BAB9070B5F61

P577

Q24634660-D49F7B80-5900-41AC-A96B-140737647555

P5875

Q24634660-2428F90B-7020-4291-95B8-175F47EF0CE1

P698

Q24634660-EC1511E0-4811-42C1-A8BB-0ABCB8A3F2FA

P921

Q24634660-AC381FBF-01C1-4242-9D53-3F69B42C542A

P932

Q24634660-FA43EBAC-AD29-4A27-A9F3-2FD2AFFDBD42

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion

@en

P2093

A Z X Zhu

http://www.w3.org/2001/XMLSchema#string

B Faseru

http://www.w3.org/2001/XMLSchema#string

J S Ahluwalia

http://www.w3.org/2001/XMLSchema#string

K S Okuyemi

http://www.w3.org/2001/XMLSchema#string

L S Cox

http://www.w3.org/2001/XMLSchema#string

N L Benowitz

http://www.w3.org/2001/XMLSchema#string

N Nollen

http://www.w3.org/2001/XMLSchema#string

R F Tyndale

http://www.w3.org/2001/XMLSchema#string

P2860

Nicotine addiction

Behavioral and biochemical investigations of bupropion metabolites

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.

Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice.

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation.

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.

P304

771-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.186

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233411532

http://www.w3.org/2001/XMLSchema#string

P698

23149928

http://www.w3.org/2001/XMLSchema#string

P921

P932

3729209

http://www.w3.org/2001/XMLSchema#string